Results 41 to 50 of about 97,405 (387)
Toward understanding ambulatory activity decline in Parkinson disease [PDF]
, 2015 BACKGROUND: Declining ambulatory activity represents an important facet of disablement in Parkinson disease (PD). OBJECTIVE: The primary study aim was to compare the 2-year trajectory of ambulatory activity decline with concurrently evolving facets of ...
Cavanaugh, James T. +5 more
core +1 more source
Effects of levodopa on gut bacterial antibiotic resistance in Parkinson’s disease rat
Frontiers in Aging Neuroscience, 2023 The second most prevalent neurodegenerative ailment, Parkinson’s disease (PD), is characterized by both motor and non-motor symptoms. Levodopa is the backbone of treatment for PD at the moment.
Shuo Sheng +6 more
doaj +1 more source
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations [PDF]
, 2014 In the recent years, the serotonin system has emerged as a key player in the induction of l-DOPA-induced dyskinesia (LID) in animal models of Parkinson's disease. In fact, serotonin neurons possess the enzymatic machinery able to convert exogenous l-DOPA
CARTA, MANOLO, TRONCI, ELISABETTA
core +1 more source
A Wearable Sweat Band for Noninvasive Levodopa Monitoring.
Nano letters (Print), 2019 Levodopa is the standard medication clinically prescribed to patients afflicted with Parkinson's disease. In particular, the monitoring and optimization of levodopa dosage is critical to mitigate the onset of undesired fluctuations in the patients ...
Li-Chia Tai +12 more
semanticscholar +1 more source
Levodopa-induced pseudopheochromocytoma
European Journal of Case Reports in Internal Medicine, 2023 Pseudopheochromocytoma is a pathological condition presenting with paroxysmal hypertension with normal or moderate elevation in catecholamines and metanephrine levels, but no evidence of a tumoural cause. Imaging studies and I-123 metaiodobenzylguanidine scintigraphy are essential for exclusion of pheocromocytoma.
Joana Bernardino Cardoso +6 more
openaire +3 more sources
Impact of initial treatment on future symptoms and quality of life in Parkinson's disease
Chinese Journal of Contemporary Neurology and Neurosurgery, 2022 Objective To explore the effects of different initial drug treatment on motor symptoms, cognitive function and quality of life in patients with Parkinson's disease (PD).
LI Yu⁃wang +5 more
doaj +1 more source
Structural MRI Correlates of Episodic Memory Processes in Parkinson's Disease Without Mild Cognitive Impairment. [PDF]
, 2015 BackgroundChanges in episodic memory are common early in Parkinson's disease (PD) and may be a risk factor for future cognitive decline. Although medial temporal lobe (MTL) memory and frontostriatal (FS) executive systems are thought to play different ...
Filoteo, J Vincent +3 more
core +2 more sources
Neurobiology of Disease, 2016 Ras homolog enriched in striatum (Rhes) is a small GTP-binding protein that modulates signal transduction at dopamine receptors, and also activates mammalian target of rapamycin complex 1 (mTORC1). Rhes binding to mTORC1 is hypothesized to play a role in
Alberto Brugnoli +3 more
doaj +1 more source
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]
, 2015 In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani +9 more
core +3 more sources
Frontiers in Neurology, 2023 BackgroundThis study aimed to determine real-world prescribing patterns and determinants for Japanese patients with Parkinson's disease (PD), with a focus on patients ≥75 years.MethodsThis was a retrospective, observational, longitudinal study of ...
Morinobu Seki +4 more
doaj +1 more source